P. A. Maizenger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
P. A. Maizenger has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Elena B. Bashnina
North-Western State Medical University Named After I.I. Mechnikov
1 shared publication - G. G. Radulesku
Saint Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)
1 shared publication - G. I. Obraztsova
Almazov National Medical Research Center
1 shared publication - I. V. Bezyazychnaya
N.P. Napalkov Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
1 shared publication - Irina Leorovna Nikitina
Almazov National Medical Research Centre
1 shared publication - Margarita B. Belogurova
Almazov National Medical Research Centre, Ministry of Health of Russia; Saint Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological) named after N.P. Napalkov
1 shared publication
Latest Publications
- Open Access
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 91-101
Heritable TP53-related cancer syndrome and medulloblastoma in children: diagnostic and screening issues
Today, the contribution of hereditary tumor syndromes to the development of cancer in children is obvious, which determines the need for screening programs and selection of the most effective methods of anticancer therapy. One of the most aggressive hereditary tumor syndromes is heritable TP53-related cancer syndrome (hTP53rc, formerly known as Li–Fraumeni syndrome), characterized by a high risk, early onset and recurrent cases of malignant neoplasms in one patient. The article describes current data on hTP53rc syndrome and the features of its clinical course, and provides international recommendations for monitoring and cancer screening in pediatric patients with hTP53rc syndrome. As a clinical observation, we present an analysis of the registry of patients with relapsed and refractory forms of medulloblastoma (n = 241) with the assessment of its incidence in cases of germline mutations in the TP53 gene with the description of their medical history and the influence of this genetic event on the outcomes. The results of our study, as well as data from international literature, indicate unfavorable prognosis in tumors, including medulloblastoma, in patients with hTP53rc syndrome, however, such factors as early screening, surveillance and early and adequate therapy can help to increase their life expectancy. The study was approved by the Independent Ethics Committee and the Scientific Council of the Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation.
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 91-101
Open AccessHeritable TP53-related cancer syndrome and medulloblastoma in children: diagnostic and screening issues
Today, the contribution of hereditary tumor syndromes to the development of cancer in children is obvious, which determines the need for screening programs and selection of the most effective methods of anticancer therapy. One of the most aggressive hereditary tumor syndromes is heritable TP53-related cancer syndrome (hTP53rc, formerly known as Li–Fraumeni syndrome), characterized by a high risk, early onset and recurrent cases of malignant neoplasms in one patient. The article describes current data on hTP53rc syndrome and the features of its clinical course, and provides international recommendations for monitoring and cancer screening in pediatric patients with hTP53rc syndrome. As a clinical observation, we present an analysis of the registry of patients with relapsed and refractory forms of medulloblastoma (n = 241) with the assessment of its incidence in cases of germline mutations in the TP53 gene with the description of their medical history and the influence of this genetic event on the outcomes. The results of our study, as well as data from international literature, indicate unfavorable prognosis in tumors, including medulloblastoma, in patients with hTP53rc syndrome, however, such factors as early screening, surveillance and early and adequate therapy can help to increase their life expectancy. The study was approved by the Independent Ethics Committee and the Scientific Council of the Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation.